Lenalidomide Teva (Lenalidomide)

• Lenalidomide is indicated for several hematologic malignancies, acting on disease pathways that involve abnormal plasma cells and dysregulated bone marrow function.
• Multiple Myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic response in eligible patients.
• Mantle Cell Lymphoma: contributes to disease control in patients who have received prior therapies.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Their degradation leads to reduced proliferation of malignant plasma cells, enhanced immune‑mediated tumor cell killing, inhibition of angiogenesis, and modulation of cytokine production, collectively exerting antineoplastic effects. Additionally, lenalidomide influences the microenvironment by decreasing stromal support for tumor growth.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may be occasional.
• Constipation: difficulty passing stool.
• Rash: skin irritation or redness.
• Low blood counts (mild neutropenia or thrombocytopenia): reduced white cells or platelets.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: blood clots in veins.
• Severe neutropenia: markedly low white blood cell count increasing infection risk.
• Severe thrombocytopenia: very low platelet count leading to bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Hepatotoxicity: significant liver enzyme elevations or liver injury.

• Before initiating therapy, several safety considerations should be reviewed.
• Pregnancy: contraindicated; teratogenic (Category X) and requires effective contraception.
• Renal impairment: assess kidney function and adjust dose if necessary.
• Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
• Thromboembolic risk: evaluate need for prophylactic anticoagulation in high‑risk patients.
• Drug interactions: avoid concomitant use with strong CYP inducers that may lower exposure.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly decrease lenalidomide exposure.
• Anticoagulants (e.g., warfarin): can increase bleeding risk.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations.
• H2 antagonists (e.g., cimetidine): potential effect on metabolism.
• Other immunomodulatory agents: additive myelosuppression requiring blood count surveillance.